1.5 Abstract in rivista

1.5 Abstract in rivista: [2184] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 181 a 200 di 2.184

Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance

2013-01-01 Franchina, T; Russo, A; Picciotto, M; Scimone, A; Berenato, R; Noto, L; Schifano, S; Adamo, V.

Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis.

2018-01-01 Giuffrida, D; Chillari, F; Blanco, G; Russo, A; Franchina, T; Puliafito, I; Prestifilippo, A; Battaglia, A; Castorina, L; Adamo, V.

The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis

2015-01-01 Bronte, G; Franchina, T; Alù, M; Sortino, G; Celesia, C; Passiglia, F; Savio, G; Laudani, A; Russo, A; Picone, A; Rizzo, S; Blasi, L; Adamo, V; Russo, A.

PO-063: Extracellular vesicle miRNAs and autophagic CTCs: Predictive and prognostic biomarkers in radiotherapy treated NSCLC patients.

2021-01-01 De Miguel Perez, D; Tejada, Rg; Russo, A; Ortega, Fg; Martínez-Única, A; Gunasekaran, M; Lorente, Ja; Exposito, J; Fernandez, Mjs; Rolfo, C

Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non small cell lung cancer (NSCLC)

2019-01-01 Russo, A; Franchina, T; Ricciardi, G; Battaglia, A; Schifano, S; Schifilliti, M; Scimone, A; Toscano, G; Zanghì, M; Adamo, V.

The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lung cancer patients: Findings from a retrospective analysis.

2015-01-01 Bronte, G; Franchina, T; Alù, M; Sortino, G; Celesia, C; Passiglia, F; Savio, G; Laudani, A; Russo, A; Picone, A; Rizzo, S; Blasi, L; Adamo, V; Russo, A.

Impact of maintenance Pemetrexed in the management of non-progressing malignant mesotheliomas after standard fist-line chemotherapy: a single institution experience.

2015-01-01 Franchina, T; Russo, A; Picone, A; Ricciardi, Grr; Raiti, F; Scimone, A; Chiofalo, G; Toscano, G; Adamo, V.

Baseline Absolute Neutrophil Count (ANC), derived Neutrophil-to-Lymphocyte Ratio (dNLR) and Platelet-to-Lymphocyte Ratio (PLR) and outcome in Non Small Cell Lung Cancer (NSCLC) treated with Nivolumab or Docetaxel: a preliminary analysis.

2017-01-01 Russo, A; Scimone, A; Picciotto, M; Toscano, G; Raiti, F; Sava, S; Battaglia, A; Adamo, V.

55P - Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study.

2019-01-01 Nigro, O; Cortellini, A; Giusti, R; Marchetti, P; De Galitiis, F; Di Pietro, F; Bersanelli, M; Lazzarin, A; Galetta, D; Pizzutillo, P; Santini, D; Torniai, M; De Giglio, A; Russo, A; Silva, R; Bolzacchini, E; Natoli, C; Rijavec, E; Silva, R; Vallini, I; Pinotti, G.

Could EGFR Gene Mutations Provide a Selective Advantage to Malignant Cells in Specific Sites? New Perspectives in Lung Adenocarcinoma Biology.

2015-01-01 Franchina, T; Russo, A; Franchina, V; Picone, A; Ricciardi, Grr; Ferraro, G; Picciotto, M; Toscano, G; Adamo, V.

Exosomal PD-L1 expression as non-invasive biomarker for immune checkpoint inhibitors in non-small cell lung cancer.

2020-01-01 Gunasekaran, M; Russo, A; Cardona, Af; De Miguel Perez, D; Lapidus, R; Cooper, B; Kaushal, S; Adamo, V; Rolfo, C.

Impact of germline Methylenetetrahydrofolate Reductase (MTHFR) polymorphisms on Pemetrexed-based therapies In thoracic malignancies: a pilot study.

2014-01-01 Franchina, T; Russo, A; Picone, A; Ientile, R; Caccamo, D; Currò, M; Franchina, V; Chillari, F; Del Re, C; Ferraro, G; Picciotto, M; Toscano, G; Adamo, V.

Association between baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR), and platelet-to-lymphocyte ratio (PLR) and response to nivolumab (Nivo) in non-small cell lung cancer (NSCLC): A preliminary analysis.

2017-01-01 Russo, A; Scimone, A; Picciotto, M; Toscano, G; Raiti, F; Sava, S; Battaglia, A; Adamo, V.

Epidermal Growth Factor Receptor mutational status predicts patterns of metastatic spread in treatment-naïve Adenocarcinomas of the lung.

2015-01-01 Russo, A; Franchina, T; Picone, A; Raiti, F; Ricciardi, Grr; Franchina, V; Ferraro, G; Scimone, A; Toscano, G; Adamo, V.

Application of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable?

2019-01-01 Mccusker, Mg; Russo, A; Chen, J; Scilla, Ka; Mehra, R; Rolfo, Cd.

Different metastatic pattern according to the EGFR mutational status in a cohort of lung adenocarcinomas (ADCs): a single-institution report.

2015-01-01 Russo, A; Franchina, T; Picone, A; Ferraro, G; Picciotto, M; Zanghì, M; Franchina, V; Adamo, V.

Challenges of interpreting NGS liquid biopsy (LB) results in advanced NSCLC: Are ESCAT and OncoKB scales reliable?

2019-01-01 Russo, A; Mccusker, M; Chen, J; Scilla, K; Mehra, R; Gittens, A; Rolfo, C.

Activity of EGFR tyrosine kinase inhibitors (TKIs) in brain metastases from Non Small Cell Lung Cancer (NSCLC) according to the EGFR mutational status: a survival analysis.

2014-01-01 Picone, A; Franchina, T; Russo, A; Chiofalo, G; Scimone, A; Zanghì, M; Raiti, F; Agostino, Rm; Sava, S; Schifano, S; Silvestro, A; Smiroldo, V; Adamo, V.

Impact of erlotinib on overall survival in non small cell lung cancer patients: is the post progression survival a new paradigm?

2013-01-01 Franchina, Tindara; Russo, Alessandro; Proto, C; Chiofalo, G; Picciotto, Maria; Scimone, A; Toscano, G; Berenato, R; Noto, L; Adamo, Vincenzo

Dynamic levels of extracellular vesicle PD-L1 and complementary radiomics for the prediction of the response to immune checkpoint inhibitors in lung cancer patients.

2021-01-01 Rolfo, Cd; De Miguel Perez, D; Russo, A; Murat, Ak; Gunasekaran, M; Manca, P; Peterson, Cb; Mamindla, P; Er, Me; Peddagangireddy, V; Buemi, F; Cooper, B; Hester, L; Hsia, Rc; Cardona, Af; Arrieta, O; Naing, A; Kaushal, S; Serrano, Mj; Colen, Rr.

Titolo	Data di pubblicazione	Autore(i)
Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance	1-gen-2013	Franchina, T; Russo, A; Picciotto, M; Scimone, A; Berenato, R; Noto, L; Schifano, S; Adamo, V.
Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis.	1-gen-2018	Giuffrida, D; Chillari, F; Blanco, G; Russo, A; Franchina, T; Puliafito, I; Prestifilippo, A; Battaglia, A; Castorina, L; Adamo, V.
The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis	1-gen-2015	Bronte, G; Franchina, T; Alù, M; Sortino, G; Celesia, C; Passiglia, F; Savio, G; Laudani, A; Russo, A; Picone, A; Rizzo, S; Blasi, L; Adamo, V; Russo, A.
PO-063: Extracellular vesicle miRNAs and autophagic CTCs: Predictive and prognostic biomarkers in radiotherapy treated NSCLC patients.	1-gen-2021	De Miguel Perez, D; Tejada, Rg; Russo, A; Ortega, Fg; Martínez-Única, A; Gunasekaran, M; Lorente, Ja; Exposito, J; Fernandez, Mjs; Rolfo, C
Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non small cell lung cancer (NSCLC)	1-gen-2019	Russo, A; Franchina, T; Ricciardi, G; Battaglia, A; Schifano, S; Schifilliti, M; Scimone, A; Toscano, G; Zanghì, M; Adamo, V.
The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lung cancer patients: Findings from a retrospective analysis.	1-gen-2015	Bronte, G; Franchina, T; Alù, M; Sortino, G; Celesia, C; Passiglia, F; Savio, G; Laudani, A; Russo, A; Picone, A; Rizzo, S; Blasi, L; Adamo, V; Russo, A.
Impact of maintenance Pemetrexed in the management of non-progressing malignant mesotheliomas after standard fist-line chemotherapy: a single institution experience.	1-gen-2015	Franchina, T; Russo, A; Picone, A; Ricciardi, Grr; Raiti, F; Scimone, A; Chiofalo, G; Toscano, G; Adamo, V.
Baseline Absolute Neutrophil Count (ANC), derived Neutrophil-to-Lymphocyte Ratio (dNLR) and Platelet-to-Lymphocyte Ratio (PLR) and outcome in Non Small Cell Lung Cancer (NSCLC) treated with Nivolumab or Docetaxel: a preliminary analysis.	1-gen-2017	Russo, A; Scimone, A; Picciotto, M; Toscano, G; Raiti, F; Sava, S; Battaglia, A; Adamo, V.
55P - Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study.	1-gen-2019	Nigro, O; Cortellini, A; Giusti, R; Marchetti, P; De Galitiis, F; Di Pietro, F; Bersanelli, M; Lazzarin, A; Galetta, D; Pizzutillo, P; Santini, D; Torniai, M; De Giglio, A; Russo, A; Silva, R; Bolzacchini, E; Natoli, C; Rijavec, E; Silva, R; Vallini, I; Pinotti, G.
Could EGFR Gene Mutations Provide a Selective Advantage to Malignant Cells in Specific Sites? New Perspectives in Lung Adenocarcinoma Biology.	1-gen-2015	Franchina, T; Russo, A; Franchina, V; Picone, A; Ricciardi, Grr; Ferraro, G; Picciotto, M; Toscano, G; Adamo, V.
Exosomal PD-L1 expression as non-invasive biomarker for immune checkpoint inhibitors in non-small cell lung cancer.	1-gen-2020	Gunasekaran, M; Russo, A; Cardona, Af; De Miguel Perez, D; Lapidus, R; Cooper, B; Kaushal, S; Adamo, V; Rolfo, C.
Impact of germline Methylenetetrahydrofolate Reductase (MTHFR) polymorphisms on Pemetrexed-based therapies In thoracic malignancies: a pilot study.	1-gen-2014	Franchina, T; Russo, A; Picone, A; Ientile, R; Caccamo, D; Currò, M; Franchina, V; Chillari, F; Del Re, C; Ferraro, G; Picciotto, M; Toscano, G; Adamo, V.
Association between baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR), and platelet-to-lymphocyte ratio (PLR) and response to nivolumab (Nivo) in non-small cell lung cancer (NSCLC): A preliminary analysis.	1-gen-2017	Russo, A; Scimone, A; Picciotto, M; Toscano, G; Raiti, F; Sava, S; Battaglia, A; Adamo, V.
Epidermal Growth Factor Receptor mutational status predicts patterns of metastatic spread in treatment-naïve Adenocarcinomas of the lung.	1-gen-2015	Russo, A; Franchina, T; Picone, A; Raiti, F; Ricciardi, Grr; Franchina, V; Ferraro, G; Scimone, A; Toscano, G; Adamo, V.
Application of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable?	1-gen-2019	Mccusker, Mg; Russo, A; Chen, J; Scilla, Ka; Mehra, R; Rolfo, Cd.
Different metastatic pattern according to the EGFR mutational status in a cohort of lung adenocarcinomas (ADCs): a single-institution report.	1-gen-2015	Russo, A; Franchina, T; Picone, A; Ferraro, G; Picciotto, M; Zanghì, M; Franchina, V; Adamo, V.
Challenges of interpreting NGS liquid biopsy (LB) results in advanced NSCLC: Are ESCAT and OncoKB scales reliable?	1-gen-2019	Russo, A; Mccusker, M; Chen, J; Scilla, K; Mehra, R; Gittens, A; Rolfo, C.
Activity of EGFR tyrosine kinase inhibitors (TKIs) in brain metastases from Non Small Cell Lung Cancer (NSCLC) according to the EGFR mutational status: a survival analysis.	1-gen-2014	Picone, A; Franchina, T; Russo, A; Chiofalo, G; Scimone, A; Zanghì, M; Raiti, F; Agostino, Rm; Sava, S; Schifano, S; Silvestro, A; Smiroldo, V; Adamo, V.
Impact of erlotinib on overall survival in non small cell lung cancer patients: is the post progression survival a new paradigm?	1-gen-2013	Franchina, Tindara; Russo, Alessandro; Proto, C; Chiofalo, G; Picciotto, Maria; Scimone, A; Toscano, G; Berenato, R; Noto, L; Adamo, Vincenzo
Dynamic levels of extracellular vesicle PD-L1 and complementary radiomics for the prediction of the response to immune checkpoint inhibitors in lung cancer patients.	1-gen-2021	Rolfo, Cd; De Miguel Perez, D; Russo, A; Murat, Ak; Gunasekaran, M; Manca, P; Peterson, Cb; Mamindla, P; Er, Me; Peddagangireddy, V; Buemi, F; Cooper, B; Hester, L; Hsia, Rc; Cardona, Af; Arrieta, O; Naing, A; Kaushal, S; Serrano, Mj; Colen, Rr.

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 181 a 200 di 2.184

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext2131
reserved51
open2